-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is a devastating progressive neurodegenerative disease with a high incidence worldwide
.
Recent drug trials for patients with dementia and potential AD have failed to show meaningful benefits
prevention
Almost all carriers of the DIAD mutation (DIAD-MC) develop dementia
.
Although the onset time of dementia can be estimated based on the age of onset of symptoms of patients with the same type of dementia, their age of onset generally varies by several years, even in the same family
Recently, researchers created a dementia risk score by inputting the normalized gray matter volume of 231 DIAD-MCs into logistic regression to classify participants with and without dementia
.
The Cox model and receiver operating curve were used to longitudinally track another group of 65 DIAD-MCs to evaluate the predictive utility of the scores
The brain map shows the relative weight of each region of interest (ROI) in the atrophy-based dementia risk score
The brain map shows the relative weight of each region of interest (ROI) in the atrophy-based dementia risk score.Use 96.
It can be used to establish the selection criteria for prevention trials and the stratification of DIAD-MC participants.
Original source:
Original source:Ophir Keret et al.
Ophir Keret et al.
Leave a message here
